インスリン送達デバイス市場：タイプ別（インスリンペン[再利用可能、使い捨て]、インスリンポンプ（テザー、チューブレス）、インスリンシリンジ、インスリンペン針（標準、安全））、エンドユーザー別（病院・クリニック、患者・在宅ケア）-2028年までの世界予測

Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standard, Safety)), End User (Hospitals & Clinics, Patients/Homecare) - Global Forecast to 2028

世界のインスリン送達デバイス市場は、2023年の308億米ドルから2028年には462億米ドルに達すると予測され、予測期間中のCAGRは8.5%である。インスリン送達デバイス市場の成長は、主に糖尿病人口の有病率の増加、... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年7月31日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	230	210	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のインスリン送達デバイス市場は、2023年の308億米ドルから2028年には462億米ドルに達すると予測され、予測期間中のCAGRは8.5%である。インスリン送達デバイス市場の成長は、主に糖尿病人口の有病率の増加、政府の支援と有利な償還制度、インスリン送達デバイスの技術進歩などの要因によって駆動される。一方、発展途上国におけるインスリン送達デバイスシステムの高コストと償還不足は、市場の成長をある程度抑制すると予想される。

インスリンポンプ分野は予測期間中に最も高いCAGRで成長すると予測されている。タイプ別に見ると、世界のインスリン送達デバイス市場は、インスリンペン、インスリンポンプ、インスリンペン針、インスリン注射器、および経皮インスリンパッチ、インスリンジェット注射器、インスリン吸入器を含むその他のインスリン送達デバイスに区分される。インスリンポンプ部門は、さらにテザーインスリンポンプとチューブレスインスリンポンプに細分化される。より新しく洗練された技術により、インスリンポンプはケアの質と使いやすさの点で革命的な進歩を遂げ、血糖コントロールが改善された。

患者/在宅ケアエンドユーザーセグメントは予測期間中に最も高いCAGRで成長すると予測されるエンドユーザー別に見ると、インスリン送達デバイス市場は患者/在宅ケアと病院＆クリニックに区分される。患者/在宅ケアセグメントは予測期間中に最も高いCAGRで成長すると予測されている。これは主に、糖尿病ケア機器に対する意識の高まり、糖尿病医療費の増加、有利な償還の結果、在宅ケアに対する患者の受け入れが増加していることに起因する。

地域別では北米がインスリン送達デバイス市場で最大シェアを占めると予測
地域別に見ると、インスリン送達デバイス市場は北米、欧州、アジア太平洋地域、その他の地域に区分される。2022年のインスリン送達デバイス市場は北米が支配的であった。コネクテッド糖尿病管理デバイスの成長、糖尿病人口の増加、技術的に先進的な製品に対する需要、政府の取り組み、この地域における自己糖尿病管理に対する意識の高まりが、北米がインスリンデリバリーデバイス市場を支配する主な要因となっている。

供給側の一次インタビューの内訳- 企業タイプ別：企業タイプ別：Tier 1 - 46%、Tier 2 - 33%、Tier 3 - 21%：Cレベル - 43%、ディレクターレベル - 35%、その他 - 22% - 地域別：地域別：北米34％、欧州26％、APAC19％、その他21
世界のインスリン送達デバイス市場で事業を展開している主要企業は、Embecta Corp. (Formely Becton, Dickinson and Company Diabetes Care Business (米国)、Ypsomed Holding AG (スイス)、Tandem Diabetes Care (米国)、Insulet Corporation (米国)、Biocon Limited (インド)、Novo Nordisk A/S (デンマーク)、Medtronic (アイルランド)、Sanofi (フランス)、Eli Lilly and Company (米国)、Roche Diabetes Care (スイス)、Owen Mumford (英国)、Mrdtrum Technologies Inc.(中国)、テルモ(日本)、Wockhardt(インド)、Cerur Corporation(スイス)、EoFlow CO、Ltd.（韓国(韓国）、Hindustan Syringes & Medical Devices Ltd（インド）、Sooil Developments CO., Ltd（韓国）、Sungshim Medical Co.(Ltd.（韓国）、Vicentra B.V.（オランダ）、Debiotech SA（スイス）、Jiangsu Delfu Medical Device Co.Ltd.（中国）、Haselmeier（ドイツ）、Mannkind Corporation（米国）、HTL-Sterfa S.A.（ポーランド）。

調査範囲
本レポートでは、インスリン送達デバイス市場をタイプ、用途、製品、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を調査しています。市場における機会と課題を分析し、市場リーダーのための競争状況の詳細を提供しています。さらに、個々の成長動向に関してミクロ市場を分析し、4つの主要地域とそれぞれの国に関して市場セグメントの収益を予測しています。

レポート購入の理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業にとっても、市場の動向を把握する上で有益であり、ひいては市場シェアを拡大する上で役立つものと思われる。本レポートを購入される企業は、以下の戦略のいずれか、または任意の組み合わせを使用して、市場での地位を強化することができます。

本レポートは、以下のポイントに関する洞察を提供する：
- 主な促進要因（糖尿病人口の増加、インスリン送達デバイスの技術進歩、市場成長を促進する政府支援と有利な償還スキーム）、阻害要因（発展途上国における高コストと償還不足、ペン型注射針・シリンジ市場の成長に影響を与える患者の注射針への不安、代替薬物送達方法としての経口インスリン）、機会（研究開発活動と戦略的パートナーシップの増加、シリンジと技術の進歩）、課題（針刺し損傷と注射ペンの誤用）の分析。
- 製品開発／イノベーション：世界のインスリン送達デバイス市場における今後の動向、研究開発活動、新製品発売に関する詳細な洞察
- 市場開発：タイプ別、エンドユーザー別、地域別の有利な新興市場に関する包括的情報。
- 市場の多様化：世界のインスリン送達装置市場における新製品や製品強化、成長地域、最近の開発、投資に関する網羅的な情報。
- 競合評価：インスリン送達デバイスの世界市場における主要企業の市場シェア、成長戦略、製品提供、企業評価象限、能力を詳細に評価します。また、本レポートは、関係者が分子品質管理市場の鼓動を理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

ページTOPに戻る

1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.2.1 INCLUSIONS & EXCLUSIONS 21
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 22
1.3.2 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 23
1.5 LIMITATIONS 23
1.6 STAKEHOLDERS 23
1.7 SUMMARY OF CHANGES 23
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
FIGURE 1 INSULIN DELIVERY DEVICES MARKET: RESEARCH DESIGN 25
2.1.1 SECONDARY DATA 26
2.1.1.1 Key data from secondary sources 27
2.1.2 PRIMARY DATA 27
FIGURE 2 PRIMARY SOURCES 27
2.1.2.1 Key data from primary sources 28
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 29
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION 30
2.2 MARKET SIZE ESTIMATION 30
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2022) 31
FIGURE 6 MARKET SIZE ESTIMATION: COMPANY-WISE REVENUE SHARE ANALYSIS (2022) 31
FIGURE 7 INSULIN DELIVERY DEVICES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 33
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF INSULIN DELIVERY DEVICES MARKET 34
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 35
FIGURE 9 DATA TRIANGULATION METHODOLOGY 35
2.4 MARKET SHARE ESTIMATION 36
2.5 STUDY ASSUMPTIONS 36
2.6 IMPACT OF RECESSION 36
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS. 2021–2027 (%GROWTH) 36
3 EXECUTIVE SUMMARY 38
FIGURE 10 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 38
FIGURE 11 INSULIN DELIVERY DEVICES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 39
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF INSULIN DELIVERY DEVICES MARKET 40
4 PREMIUM INSIGHTS 41
4.1 INSULIN DELIVERY DEVICES: MARKET OVERVIEW 41
FIGURE 13 INCREASING TECHNOLOGICAL ADVANCEMENTS IN INSULIN DELIVERY DEVICES TO DRIVE MARKET 41
4.2 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE AND COUNTRY (2022) 42
FIGURE 14 INSULIN PENS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 42
4.3 INSULIN DELIVERY DEVICES MARKET: GEOGRAPHICAL MIX 43
FIGURE 15 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 43
4.4 INSULIN DELIVERY DEVICES MARKET: REGIONAL MIX (2023–2028) 44
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023–2028) 44
4.5 INSULIN DELIVERY DEVICES MARKET: DEVELOPED VS. DEVELOPING MARKETS 44
FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 44
5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
FIGURE 18 INSULIN DELIVERY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 45
5.2.1 DRIVERS 46
5.2.1.1 Growing prevalence of diabetic population 46
FIGURE 19 GLOBAL PREVALENCE OF DIABETES IN INDIVIDUALS AGED 20–79 YEARS, 2015–2021 (MILLIONS) 46
FIGURE 20 PROJECTION OF DIABETES FOR INDIVIDUALS AGED 20–79 YEARS, 2030-2045 (MILLIONS) 47
FIGURE 21 TOP TEN COUNTRIES WITH HIGHEST COUNT OF DIABETICS (20–79 YEARS), 2021 & 2045 47
5.2.1.2 Technological advancements in insulin delivery devices 48
FIGURE 22 ADVANCEMENTS IN INSULIN DELIVERY DEVICES 49
5.2.1.3 Government support and favorable reimbursement schemes to favor market growth 49
5.2.2 RESTRAINTS 50
5.2.2.1 High costs and lack of reimbursement in developing countries 50
5.2.2.2 Needle anxiety in patients to affect growth of pen needles and syringes market 50
5.2.2.3 Oral insulin as alternative drug delivery method 50
5.2.3 OPPORTUNITIES 51
5.2.3.1 Increasing R&D activities and strategic partnerships 51
5.2.3.2 Increasing healthcare expenditure on diabetes care 52
FIGURE 23 TOTAL HEALTH EXPENDITURE ON DIABETES CARE, 2021–2045 (USD BILLION) 52
5.2.3.3 Advances in syringe and needle technology 52
5.2.3.4 Mandates pertaining to safety-engineered medical needles to encourage market growth 53
5.2.4 CHALLENGES 53
5.2.4.1 Needlestick injuries and misuse of injection pens 53
5.2.4.2 Lack of interoperability among insulin delivery devices 54
5.3 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 2 INSULIN DELIVERY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 55
5.3.1 INTENSITY OF COMPETITIVE RIVALRY 55
5.3.2 BARGAINING POWER OF SUPPLIERS 55
5.3.3 BARGAINING POWER OF BUYERS 55
5.3.4 THREAT OF SUBSTITUTES 56
5.3.5 THREAT OF NEW ENTRANTS 56
5.4 REGULATORY ANALYSIS 56
TABLE 3 INDICATIVE LIST OF REGULATORY AUTHORITIES 56
5.4.1 NORTH AMERICA 57
5.4.1.1 US 57
TABLE 4 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 57
FIGURE 24 FDA 510(K) APPROVAL PROCESS 58
5.4.1.2 Canada 58
5.4.2 EUROPE 59
FIGURE 25 CE MARK APPROVAL PROCESS FOR INSULIN DELIVERY DEVICES 60
5.4.3 ASIA PACIFIC 61
5.4.3.1 Japan 61
TABLE 5 JAPAN: CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY 61
5.4.3.2 China 61
TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 61
5.4.3.3 India 61
TABLE 7 INDIA: MEDICAL DEVICE CLASSIFICATION 62
5.4.3.4 Australia 62
FIGURE 26 SUMMARY OF APPROVAL, ACCESS, AND DISTRIBUTION PATHWAYS FOR NEW TECHNOLOGY USED FOR INSULIN DRUG DELIVERY DEVICES 63
5.4.4 REST OF THE WORLD 63
5.5 INDUSTRY INSIGHTS 63
5.5.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS 63
TABLE 8 HYBRID CLOSED-LOOP SYSTEMS: CURRENT MARKET SCENARIO 64
5.5.2 SYNCHRONIZATION OF SMART INSULIN PENS WITH CGM SYSTEMS TO PROMOTE DIABETES DATA SHARING 64
TABLE 9 MAJOR SMART INSULIN PENS AVAILABLE GLOBALLY 65
5.5.3 INCREASING NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS 65
TABLE 10 INSULIN DELIVERY DEVICE MARKET: RECENT COLLABORATIONS 65
5.6 REIMBURSEMENT SCENARIO 66
TABLE 11 INSULIN DELIVERY DEVICES: GLOBAL COVERAGE AND REIMBURSEMENT 66
5.6.1 US 66
5.6.2 CANADA 67
5.6.3 UK 67
5.6.4 AUSTRALIA 68
5.6.5 OTHER COUNTRIES 68
5.7 TECHNOLOGICAL ANALYSIS 68
5.8 KEY CONFERENCES & EVENTS, 2023–2024 69
TABLE 12 INSULIN DELIVERY DEVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.9 PRICING ANALYSIS 69
5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT 70
TABLE 13 AVERAGE SELLING PRICE OF INSULIN PENS, BY KEY PLAYER 70
TABLE 14 AVERAGE SELLING PRICE OF INSULIN PUMPS, BY KEY PLAYER 70
5.10 PATENT ANALYSIS 71
FIGURE 27 PATENT PUBLICATION TRENDS (JANUARY 2011–MAY 2023) 72
5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 72
FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR INSULIN DELIVERY DEVICES PATENTS (JANUARY 2011–MAY 2023) 73
FIGURE 29 TOP APPLICANT COUNTRIES/REGIONS FOR INSULIN DELIVERY DEVICES (JANUARY 2011–MAY 2023) 74
5.11 VALUE CHAIN ANALYSIS 74
FIGURE 30 INSULIN DELIVERY DEVICES MARKET: VALUE CHAIN ANALYSIS 75
5.12 ECOSYSTEM MARKET MAP 75
FIGURE 31 INSULIN DELIVERY DEVICE MARKET: ECOSYSTEM MAPPING 77
5.13 USE CASES 77
TABLE 15 T:SLIM X2 INSULIN PUMPS TO OFFER CONTINUED IMPROVEMENTS IN FUNCTIONALITY, SAFETY, AND WEARABILITY OF PUMPS 77
TABLE 16 AUTOMATED AND SMART INSULIN DELIVERY DEVICE FOR DIABETES CARE 78
TABLE 17 CONTRIBUTION OF SMART INSULIN PEN IN LIGHTENING DIABETES MANAGEMENT LOAD 78
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INSULIN DELIVERY DEVICES 79
5.14.2 BUYING CRITERIA FOR INSULIN DELIVERY DEVICES 79
FIGURE 33 KEY BUYING CRITERIA FOR END USERS 79

6 INSULIN DELIVERY DEVICES MARKET, BY TYPE 80
6.1 INTRODUCTION 81
TABLE 18 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 81
TABLE 19 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (THOUSAND UNITS) 81
6.2 INSULIN PENS 82
6.2.1 ADVANCED AND CONVENIENT SOLUTIONS FOR INSULIN ADMINISTRATION TO DRIVE MARKET 82
TABLE 20 INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 82
TABLE 21 INSULIN PENS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 22 INSULIN PENS MARKET, BY REGION, 2021–2028 (THOUSAND UNITS) 83
6.2.2 REUSABLE INSULIN PENS 83
6.2.2.1 Technology innovations to boost growth 83
TABLE 23 REUSABLE INSULIN PENS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.2.3 DISPOSABLE INSULIN PENS 85
6.2.3.1 Shift toward eco-friendly environment to restrain growth of market during forecast period 85
TABLE 24 DISPOSABLE INSULIN PENS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
6.3 INSULIN PUMPS 86
6.3.1 NEWER AND MORE REFINED TECHNOLOGY TO DRIVE INSULIN PUMPS MARKET 86
TABLE 25 INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 87
TABLE 26 INSULIN PUMPS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 27 INSULIN PUMPS MARKET, BY REGION, 2021–2028 (THOUSAND UNITS) 88
6.3.2 TETHERED INSULIN PUMPS 89
6.3.2.1 Increasing collaborations and partnerships between companies to develop integrated CGM systems to drive market 89
TABLE 28 TETHERED INSULIN PUMPS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
6.3.3 TUBELESS INSULIN PUMPS 90
6.3.3.1 Use of artificial intelligence and technological advancements to boost market 90
TABLE 29 TUBELESS INSULIN PUMPS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91
6.4 INSULIN PEN NEEDLES 91
TABLE 30 INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 92
TABLE 31 INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 32 INSULIN PEN NEEDLES MARKET, BY REGION, 2021–2028 (THOUSAND UNITS) 93
6.4.1 STANDARD INSULIN PEN NEEDLES 93
6.4.1.1 Affordability of standard insulin pen needles over safety pen needles to propel growth 93
TABLE 33 STANDARD INSULIN PEN NEEDLES OFFERED BY KEY PLAYERS 93
TABLE 34 STANDARD INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
6.4.2 SAFETY INSULIN PEN NEEDLES 94
6.4.2.1 Reducing chances of infection and accidental pricking to drive market 94
TABLE 35 SAFETY INSULIN PEN NEEDLES OFFERED BY KEY PLAYERS 95
TABLE 36 SAFETY INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
6.5 INSULIN SYRINGES 96
6.5.1 SAFETY CONCERNS AND INCREASING AWARENESS OF AFFORDABLE ALTERNATIVES TO RESTRAIN GROWTH 96
TABLE 37 INSULIN SYRINGES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 38 INSULIN SYRINGES MARKET, BY REGION, 2021–2028 (THOUSAND UNITS) 97
6.6 OTHER INSULIN DELIVERY DEVICES 98
TABLE 39 OTHER INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 40 OTHER INSULIN DELIVERY DEVICES MARKET, BY REGION, 2021–2028 (THOUSAND UNITS) 99
7 INSULIN DELIVERY DEVICES MARKET, BY END USER 100
7.1 INTRODUCTION 101
TABLE 41 INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 101
7.2 PATIENTS/HOME CARE 101
7.2.1 INCREASING AFFORDABILITY OF SELF-MONITORING SYSTEMS AND INSULIN DELIVERY DEVICES TO FUEL GROWTH 101
TABLE 42 INSULIN DELIVERY DEVICES MARKET FOR PATIENTS/HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.3 HOSPITALS & CLINICS 103
7.3.1 RISING DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS TO BOOST MARKET 103
TABLE 43 INSULIN DELIVERY DEVICES MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION) 103
8 INSULIN DELIVERY DEVICES MARKET, BY REGION 104
8.1 INTRODUCTION 105
FIGURE 34 INSULIN DELIVERY DEVICES MARKET: GEOGRAPHIC SNAPSHOT 105
TABLE 44 INSULIN DELIVERY DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 106
8.2 NORTH AMERICA 106
8.2.1 NORTH AMERICA: RECESSION IMPACT 106
FIGURE 35 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET SNAPSHOT 107
TABLE 45 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 46 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 47 NORTH AMERICA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 48 NORTH AMERICA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 49 NORTH AMERICA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 50 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 109
8.2.2 US 110
8.2.2.1 Rising prevalence of diabetes and favorable reimbursement scenario to drive market 110
8.2.2.2 Growing venture capital investments and issuance of IPOs to propel market growth 110
TABLE 51 US: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 52 US: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 53 US: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 54 US: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 55 US: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 112
8.2.3 CANADA 112
8.2.3.1 High prevalence of diabetes and favorable reimbursement for insulin delivery devices to boost market 112
TABLE 56 CANADA: ELIGIBILITY FOR INSULIN PUMPS AND SUPPLIES FOR TYPE I DIABETES, APRIL 2021 113
8.2.3.2 Regulations for usage of safety-engineered needles to drive market 114
TABLE 57 CANADA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 58 CANADA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 59 CANADA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 60 CANADA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 61 CANADA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 116
8.3 EUROPE 116
8.3.1 EUROPE: RECESSION IMPACT 116
8.3.1.1 EU’s directive on prevention of sharps injuries in hospitals and healthcare sector to drive market 117
TABLE 62 EUROPE: INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 63 EUROPE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 64 EUROPE: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 65 EUROPE: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 66 EUROPE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 67 EUROPE: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 119
8.3.2 GERMANY 119
8.3.2.1 High prevalence of diabetes and favorable reimbursement for insulin devices to propel market 119
TABLE 68 GERMANY: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 69 GERMANY: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 70 GERMANY: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 71 GERMANY: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 72 GERMANY: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 121
8.3.3 UK 121
8.3.3.1 Role of Diabetes UK in research and diabetes care to boost market 121
8.3.3.2 Insulin pump penetration to boost market 122
TABLE 73 UK: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 74 UK: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 75 UK: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 76 UK: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 77 UK: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 124
8.3.4 FRANCE 124
8.3.4.1 High insurance coverage and increasing affordability to drive market 124
TABLE 78 FRANCE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 79 FRANCE: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 80 FRANCE: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 81 FRANCE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 82 FRANCE: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 126
8.3.5 ITALY 126
8.3.5.1 Regional variations in terms of coverage and benefits to hinder market growth 126
TABLE 83 ITALY: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 84 ITALY: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 85 ITALY: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 86 ITALY: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 87 ITALY: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 128

8.3.6 SPAIN 128
8.3.6.1 Regulations for mandatory use of safety needles and increase in diabetic population to propel market 128
TABLE 88 SPAIN: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 89 SPAIN: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 90 SPAIN: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 91 SPAIN: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 92 SPAIN: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 130
8.3.7 REST OF EUROPE 130
8.3.7.1 Strong presence of major insulin delivery device manufacturers to drive market 130
TABLE 93 INDICATIVE LIST OF COMPANIES HEADQUARTERED IN REST OF EUROPE 131
FIGURE 36 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETICS (20–79 YEARS) IN MILLIONS 132
TABLE 94 REST OF EUROPE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 95 REST OF EUROPE: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 96 REST OF EUROPE: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 97 REST OF EUROPE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 98 REST OF EUROPE: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 134
8.4 ASIA PACIFIC 134
8.4.1 ASIA PACIFIC: RECESSION IMPACT 134
FIGURE 37 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET SNAPSHOT 135
8.4.1.1 High diabetes incidence and population in Asia Pacific to boost market 136
TABLE 99 ASIA PACIFIC: DIABETES PREVALENCE, BY COUNTRY 136
8.4.1.2 Partnerships among global and local players in Asia Pacific to drive market 136
TABLE 100 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 101 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 102 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 103 ASIA PACIFIC: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 104 ASIA PACIFIC: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 105 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 139

8.4.2 JAPAN 139
8.4.2.1 High adoption of insulin pens and approval of injectable insulin to propel growth 139
TABLE 106 JAPAN: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 107 JAPAN: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 108 JAPAN: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 109 JAPAN: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 110 JAPAN: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 141
8.4.3 CHINA 141
8.4.3.1 Sharp increase in diabetes in past decade and government support to drive market 141
TABLE 111 CHINA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 112 CHINA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 113 CHINA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 114 CHINA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 115 CHINA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 144
8.4.4 INDIA 144
8.4.4.1 Government initiatives to promote domestic manufacture of medical devices to drive market 144
TABLE 116 INDIA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 117 INDIA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 118 INDIA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 119 INDIA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 120 INDIA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 146
8.4.5 REST OF ASIA PACIFIC 146
8.4.5.1 Vietnam: Large diabetic population to boost market 146
8.4.5.2 Australia: Government initiatives to broaden patient access to diabetes products 147
TABLE 121 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 122 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 123 ASIA PACIFIC: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 124 ASIA PACIFIC: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 125 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 149

8.5 REST OF THE WORLD 149
8.5.1 REST OF THE WORLD: RECESSION IMPACT 150
8.5.1.1 Increasing diabetic population to propel market 150
FIGURE 38 AFRICA: TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETICS (20–79 YEARS) 151
8.5.1.2 Favorable government policies and increasing prevalence of diabetic population to drive market 151
FIGURE 39 COUNT OF DIABETICS (20–79 YEARS) IN LATIN AMERICA REGION: TOP FIVE COUNTRIES 152
TABLE 126 REST OF THE WORLD: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 127 REST OF THE WORLD: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 128 REST OF THE WORLD: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 129 REST OF THE WORLD: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 130 REST OF THE WORLD: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION) 154
9 COMPETITIVE LANDSCAPE 155
9.1 OVERVIEW 155
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 155
TABLE 131 INSULIN DELIVERY DEVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 155
9.3 MARKET SHARE ANALYSIS 158
FIGURE 40 MARKET SHARE ANALYSIS FOR INSULIN PENS, BY KEY PLAYERS, 2022 158
FIGURE 41 MARKET SHARE ANALYSIS FOR INSULIN PUMPS, BY KEY PLAYERS, 2022 158
FIGURE 42 MARKET SHARE ANALYSIS FOR INSULIN PEN NEEDLES, BY KEY PLAYERS, 2022 159
FIGURE 43 MARKET SHARE ANALYSIS FOR INSULIN SYRINGES, BY KEY PLAYERS, 2022 159
9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 160
FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022) 160
9.5 MARKET RANKING ANALYSIS 160
FIGURE 45 INSULIN DELIVERY DEVICES MARKET RANKING, BY KEY PLAYERS, 2022 161
9.6 COMPANY EVALUATION QUADRANT: KEY PLAYERS 162
9.6.1 STARS 162
9.6.2 EMERGING LEADERS 162
9.6.3 PERVASIVE PLAYERS 162
9.6.4 PARTICIPANTS 162
FIGURE 46 INSULIN DELIVERY DEVICES MARKET: COMPETITIVE LEADERSHIP MAPPING (2022) 163

9.7 COMPANY EVALUATION QUADRANT: START-UPS & SMES 163
9.7.1 PROGRESSIVE COMPANIES 163
9.7.2 DYNAMIC COMPANIES 164
9.7.3 STARTING BLOCKS 164
9.7.4 RESPONSIVE COMPANIES 164
FIGURE 47 INSULIN DELIVERY DEVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS (2022) 164
9.8 COMPANY FOOTPRINT OF PLAYERS IN INSULIN DELIVERY DEVICES MARKET 165
TABLE 132 INSULIN DELIVERY DEVICES MARKET: COMPANY FOOTPRINT (2022) 165
9.8.1 TYPE FOOTPRINT 166
TABLE 133 INSULIN DELIVERY DEVICES MARKET: TYPE FOOTPRINT (2022) 166
9.8.2 REGIONAL FOOTPRINT 167
TABLE 134 INSULIN DELIVERY DEVICES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS (2022) 167
9.9 COMPETITIVE SCENARIO 168
9.9.1 PRODUCT LAUNCHES 168
TABLE 135 PRODUCT LAUNCHES, JANUARY 2019–JUNE 2023 168
9.9.2 DEALS 169
TABLE 136 DEALS, JANUARY 2019–JUNE 2023 169
9.9.3 OTHER DEVELOPMENTS 169
TABLE 137 OTHER DEVELOPMENTS, JANUARY 2019–JUNE 2023 169
10 COMPANY PROFILES 171
10.1 KEY PLAYERS 171
(Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)*
10.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS) 171
TABLE 138 EMBECTA CORP.: COMPANY OVERVIEW 171
FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 172
10.1.2 NOVO NORDISK A/S 175
TABLE 139 NOVO NORDISK A/S: COMPANY OVERVIEW 175
FIGURE 49 NOVO NORDISK A/S: COMPANY SNAPSHOT (2022) 176
10.1.3 MEDTRONIC PLC 179
TABLE 140 MEDTRONIC PLC: COMPANY OVERVIEW 179
FIGURE 50 MEDTRONIC PLC: COMPANY SNAPSHOT (2022) 180
10.1.4 SANOFI 184
TABLE 141 SANOFI: COMPANY OVERVIEW 184
FIGURE 51 SANOFI: COMPANY SNAPSHOT (2022) 185
10.1.5 LILLY 188
TABLE 142 LILLY: COMPANY OVERVIEW 188
FIGURE 52 LILLY: COMPANY SNAPSHOT (2022) 188

10.1.6 YPSOMED HOLDING AG 191
TABLE 143 YPSOMED HOLDING AG: COMPANY OVERVIEW 191
FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2023) 192
10.1.7 TANDEM DIABETES CARE, INC. 194
TABLE 144 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW 194
FIGURE 54 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2022) 194
10.1.8 INSULET CORPORATION 197
TABLE 145 INSULET CORPORATION: COMPANY OVERVIEW 197
FIGURE 55 INSULET CORPORATION: COMPANY SNAPSHOT (2022) 197
10.1.9 BIOCON LIMITED 200
TABLE 146 BIOCON LIMITED: COMPANY OVERVIEW 200
FIGURE 56 BIOCON LIMITED: COMPANY SNAPSHOT (2022) 201
10.1.10 ROCHE DIABETES CARE 202
TABLE 147 F. HOFFMANN-LA ROCHE: COMPANY OVERVIEW 202
FIGURE 57 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2022) 202
10.1.11 OWEN MUMFORD 204
TABLE 148 OWEN MUMFORD: COMPANY OVERVIEW 204
10.1.12 MEDTRUM TECHNOLOGIES INC. 206
TABLE 149 MEDTRUM TECHNOLOGIES INC.: COMPANY OVERVIEW 206
10.1.13 TERUMO CORPORATION 207
TABLE 150 TERUMO CORPORATION: COMPANY OVERVIEW 207
FIGURE 58 TERUMO CORPORATION: COMPANY SNAPSHOT (2021) 208
10.1.14 WOCKHARDT 210
TABLE 151 WOCKHARDT: COMPANY OVERVIEW 210
FIGURE 59 WOCKHARDT: COMPANY SNAPSHOT (2021) 210
*Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS 212
10.2.1 CEQUR CORPORATION 212
10.2.2 EOFLOW CO., LTD. 212
10.2.3 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD 213
10.2.4 SOOIL DEVELOPMENTS CO., LTD 214
10.2.5 SUNGSHIM MEDICAL CO., LTD. 215
10.2.6 VICENTRA B.V. 216
10.2.7 DEBIOTECH SA 216
10.2.8 JIANGSU DELFU MEDICAL DEVICE CO., LTD 217
10.2.9 HASELMEIER 218
10.2.10 MANNKIND CORPORATION 219
10.2.11 HTL-STREFA S.A. 219

11 APPENDIX 220
11.1 DISCUSSION GUIDE 220
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 226
11.3 CUSTOMIZATION OPTIONS 228
11.4 RELATED REPORTS 228
11.5 AUTHOR DETAILS 229

ページTOPに戻る

Table of Contents

Summary

The global insulin delivery devices market is projected to reach USD 46.2 billion by 2028 from USD 30.8 billion in 2023, at a CAGR of 8.5% during the forecast period. Growth in the insulin delivery devices market is mainly driven by factors such as the growing prevalence of diabetic population, government support and favorable reimbursement schemes, technological advancements in insulin delivery devices. On the other hand, the high costs and lack of reimbursements in developing countries of insulin delivery devices systems are expected to restrain market growth to a certain extent.

Insulin pumps segment is projected to grow at the highest CAGR during the forecast period By type, the global insulin delivery devices market is segmented into insulin pens, insulin pumps, insulin pen needles, insulin syringes and other insulin delivery devices which includes, transdermal insulin patch, insulin jet injectors, insulin inhalers. The insulin pump segment is further sub-segmented into tethered insulin pumps and tubeless insulin pumps. As newer and more refined technology has now revolutionized insulin pumps in terms of their quality of care, and ease of use resulting in improved glycemic control, in addition favourable reimbursement in developed countries is contributing towards the adoption of these devices as a result this segment is projected to have the highest CAGR in the forecast period.

Patients/Homecare end user segment is projected to grow at the highest CAGR during the forecast period By end users, the insulin delivery devices market is segmented into patients/ homecare and hospitals & clinics. The patients/home care segment is expected to grow at the highest CAGR during the forecast period. This is primarily attributed to the rising patient acceptance of home care as a result of growing awareness of diabetes care devices, increasing diabetic healthcare expenditure and favourable reimbursements.

By region, North America is projected to account for the largest share of the insulin delivery devices market
Based on region, the insulin delivery devices market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America dominated the insulin delivery devices market in 2022. The growth of connected diabetes management devices, the rising diabetic population, demand for technologically advanced products, government initiatives, and increasing awareness of self-diabetes management in the region are the main factors driving North America to dominate the insulin delivery devices market.

Breakdown of supply-side primary interviews: • By Company Type: Tier 1 – 46%, Tier 2 – 33%, and Tier 3 – 21% • By Designation: C-level – 43%, Director-level – 35%, and Others – 22% • By Region: North America - 34%, Europe – 26%, APAC –19%, Rest of World–21%
The prominent players operating in the global insulin delivery devices market are Embecta Corp. (Formely Becton, Dickinson and Company Diabetes Care Business (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), Insulet Corporation (US), Biocon Limited (India), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Eli Lilly and Company (US), Roche Diabetes Care (Switzerland), Owen Mumford (England), Mrdtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt (India), Cerur Corporation (Switzerland), EoFlow CO., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd (India), Sooil Developments CO., Ltd (Korea), Sungshim Medical Co., Ltd. (South Korea), Vicentra B.V. (Netherland), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd (China), Haselmeier (Germany), Mannkind Corporation (US), HTL-Sterfa S.A. (Poland).

Research Coverage
This report studies the insulin delivery devices market based on type, application, product, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Analysis of key drivers (growing prevalence of diabetic population, technological advancements in insulin delivery devices, government support and favourable reimbursement schemes to favour market growth), restraints (high cost and lack of reimbursement in developing countries, needle anxiety in patients to affect the growth of the pen needles and syringes market, oral insulin as an alternative drug delivery method), opportunities (increasing research and development activities and strategic partnerships, advances in syringe and technology) and challenges (Needle stick injuries and misuse of injection pens)
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global insulin delivery devices market
• Market Development: Comprehensive information on the lucrative emerging markets by type, end user, and region.
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global insulin delivery devices market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global insulin delivery devices market. This report also helps stakeholders understand the pulse of the molecular quality controls market and provides them information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（insulin）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（insulin）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?